Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

35.28
+1.564.63%
Post-market: 35.410.1300+0.37%19:56 EDT
Volume:2.49M
Turnover:86.87M
Market Cap:2.53B
PE:-5.98
High:35.57
Open:34.05
Low:34.00
Close:33.72
52wk High:56.05
52wk Low:21.15
Shares:71.71M
Float Shares:62.80M
Volume Ratio:1.65
T/O Rate:3.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8984
EPS(LYR):-4.6644
ROE:-91.75%
ROA:-46.76%
PB:6.20
PE(LYR):-7.56

Loading ...

US FDA Approves Vera's Kidney Disease Drug

Reuters
·
Jul 08

Vera Wins FDA Accelerated Approval for Trutakna in Primary Iga Nephropathy Based on 42% Proteinuria Cut in Phase 3 Trial

Reuters
·
Jul 08

Vera Therapeutics Receives FDA Accelerated Approval for Trutakna™ for Adult Patients with Primary Iga Nephropathy

THOMSON REUTERS
·
Jul 08

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

GlobeNewswire
·
Jul 08

US FDA - Approves Trutakna for Proteinuria in Primary Immunoglobulin a Nephropathy

THOMSON REUTERS
·
Jul 08

Press Release: Robinson Energy Appoints Iraida QUE DE VERA to ITS BOARD of Directors

Dow Jones
·
Jul 07

Vera Therapeutics CEO Marshall Fordyce Disposes of USD 702,065 in Common Shares

Reuters
·
Jun 25

Vera Therapeutics (VERA) Stock After FDA Trial Update Has The Valuation Gap Gone Too Far

Simply Wall St.
·
Jun 17

Vera Therapeutics (VERA) Receives a Buy from Wells Fargo

TIPRANKS
·
Jun 12

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 06

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 06

Analysts’ Top Healthcare Picks: Vera Therapeutics (VERA), Johnson & Johnson (JNJ)

TIPRANKS
·
Jun 06

Vera Therapeutics posts atacicept IgA nephropathy trial presentation

Reuters
·
Jun 05

Otsuka says kidney disease drug preserves function in late-stage study

Reuters
·
Jun 05

Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)

TIPRANKS
·
Jun 03

Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval

MT Newswires Live
·
Jun 03

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

TIPRANKS
·
Jun 03

Raymond James sees unique buying opportunity in Vera after FDA alignment

TIPRANKS
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Vera, Amtech Systems

Reuters
·
Jun 02

Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained

TIPRANKS
·
Jun 02